Cargando…

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

BACKGROUND: Use of dipeptidyl peptidase-4 inhibitors (DPP4-i) for the treatment of type 2 diabetes (T2D) has been associated with a possible increase in the risk for heart failure (HF). B-type natriuretic peptide (BNP), which is both a biomarker of HF and a hemodynamically active hormone, is a subst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fadini, Gian Paolo, Bonora, Benedetta Maria, Albiero, Mattia, Zaninotto, Martina, Plebani, Mario, Avogaro, Angelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5301429/ https://www.ncbi.nlm.nih.gov/pubmed/28183314 http://dx.doi.org/10.1186/s12933-017-0507-9

Ejemplares similares

p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

The dipeptidyl peptidase-4 inhibitor Saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients
por: Poncina, Nicol, et al.
Publicado: (2014)

How to interpret the role of SDF-1α on diabetic complications during therapy with DPP-4 inhibitors
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial
por: Fadini, Gian Paolo, et al.
Publicado: (2017)

Managing diabetes in diabetic patients with COVID: where do we start from?
por: Avogaro, Angelo, et al.
Publicado: (2021)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Response to Chia Siang Kow and colleagues
por: Avogaro, Angelo, et al.
Publicado: (2022)

Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
por: Bonora, B. M., et al.
Publicado: (2021)

Endothelial Dysfunction in Diabetes: The role of reparatory mechanisms
por: Avogaro, Angelo, et al.
Publicado: (2011)

SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
por: Bonora, Benedetta Maria, et al.
Publicado: (2021)

Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2019)

Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

Mitochondrial Calcium Uptake Is Instrumental to Alternative Macrophage Polarization and Phagocytic Activity
por: Tedesco, Serena, et al.
Publicado: (2019)

Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus
por: Mu, Liying, et al.
Publicado: (2022)

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
por: Longato, Enrico, et al.
Publicado: (2020)

Improved prediction of long-term kidney outcomes in people with type 2 diabetes by levels of circulating haematopoietic stem/progenitor cells
por: Bonora, Benedetta Maria, et al.
Publicado: (2023)

Impaired Hematopoietic Stem/Progenitor Cell Traffic and Multi-organ Damage in Diabetes
por: Fadini, Gian Paolo, et al.
Publicado: (2022)

Procalcific Phenotypic Drift of Circulating Progenitor Cells in Type 2 Diabetes with Coronary Artery Disease
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

The Use of N-Terminal-Pro-BNP in Preterm Infants
por: EL-Khuffash, Afif, et al.
Publicado: (2009)

Glycaemic Control Achieves Sustained Increases of Circulating Endothelial Progenitor Cells in Patients Hospitalized for Decompensated Diabetes: An Observational Study
por: Bonora, Benedetta Maria, et al.
Publicado: (2022)

Direct Immunochemiluminescent Assay for proBNP and Total BNP in Human Plasma proBNP and Total BNP Levels in Normal and Heart Failure
por: Nishikimi, Toshio, et al.
Publicado: (2013)

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1α
por: Fadini, Gian Paolo, et al.
Publicado: (2010)

Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
por: Avogaro, Angelo, et al.
Publicado: (2016)

Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Short-term effectiveness of dapagliflozin versus DPP-4 inhibitors in elderly patients with type 2 diabetes: a multicentre retrospective study
por: Morieri, M. L., et al.
Publicado: (2023)

Diabetes Impairs Stem Cell and Proangiogenic Cell Mobilization in Humans
por: Fadini, Gian Paolo, et al.
Publicado: (2013)

Putative circulating adipose tissue-derived stem cells, obesity, and metabolic syndrome features
por: Bonora, B. M., et al.
Publicado: (2023)

It Is All in the Blood: The Multifaceted Contribution of Circulating Progenitor Cells in Diabetic Complications
por: Fadini, Gian Paolo, et al.
Publicado: (2012)

Stem cell mobilization with plerixafor and healing of diabetic ischemic wounds: A phase IIa, randomized, double‐blind, placebo‐controlled trial
por: Bonora, Benedetta Maria, et al.
Publicado: (2020)

The Peritoneum as a Natural Scaffold for Vascular Regeneration
por: Bonvini, Stefano, et al.
Publicado: (2012)

Brain Natriuretic Peptide (BNP) and N-Terminal-proBNP in Cardio-Renal Anemia Syndrome　― Difference in Prognostic Ability ―
por: Otaki, Yoichiro, et al.
Publicado: (2019)

Cardiac Complications in Pregnancy: A Systematic Review and Meta-Analysis of Diagnostic Accuracy of BNP and N-Terminal Pro-BNP
por: Sheikh, Mahboobeh, et al.
Publicado: (2021)

Die Biomarker BNP und NT‑proBNP
por: Oremek, G. M., et al.
Publicado: (2023)

Effects of androgens on endothelial progenitor cells in vitro and in vivo
por: Fadini, Gian Paolo, et al.
Publicado: (2009)

Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor
por: Fadini, Gian Paolo, et al.
Publicado: (2015)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Comparative effectiveness of exenatide once‐weekly versus liraglutide in routine clinical practice: A retrospective multicentre study and meta‐analysis of observational studies
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP)
por: Maries, Lorena, et al.
Publicado: (2013)

N-Terminal proBNP Levels and Tissue Doppler Echocardiography in Acute Rheumatic Carditis
por: Kotby, Alyaa A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_mir7edotcnlv2b4nvg111dq34b